Market Overview

UPDATE: Stifel Nicolaus Raises PT to $40 on Theravance on Improved Risk Profile

Related THRX
Bank Of America Q3 Small & Mid-Cap Biotech Preview
Barron's Recap: Ready To Wear?

Stifel Nicolaus reiterated its Buy rating on Theravance (NASDAQ: THRX) and raised its price target from $28 to $40.

Stifel Nicolaus noted, "We believe recently-announced top-line P3 LAMA/LABA data implies a relatively clear regulatory path forward and our physician conversations suggest the utilization of these combined mechanisms of action should gain considerable traction/adoption in those moderate/severe COPD patients whom require prolonged/significant bronchodilation."

Therevance closed at $29.49 on Friday.

Latest Ratings for THRX

DateFirmActionFromTo
Jul 2014Bank of AmericaDowngradesBuyNeutral
Jun 2014Stifel NicolausDowngradesBuyHold
Jun 2014BairdDowngradesOutperformNeutral

View More Analyst Ratings for THRX
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (THRX)

Around the Web, We're Loving...

Get Benzinga's Newsletters